Ten post jest także dostępny w języku: polski
Organon said it is celebrating its launch as the only company of its size with a global footprint focused exclusively on women’s health. The company was formed by the spin-off of Merck, known as MSD outside the US and Canada.
Organon with plans to develop therapies for women
Organon EECS will be headed by Okana Isikci, who has been with Merck for over 22 years. The company will cover the Czech Republic, Slovakia, Hungary, Poland, Bulgaria, Romania, Croatia, Slovenia, Serbia, North Macedonia, Montenegro, Albania, Bosnia and Herzegovina, Greece, Cyprus and Malta. The company and its 150 employees will work in a number of areas including reproductive health, heart disease, breast cancer, allergies and asthma. Organon EECS Group will be headquartered in Prague, Czech Republic. The company has a portfolio of more than 60 drugs and products in various therapeutic areas.
On 3 June, Organon’s management announced the company’s listing on the New York Stock Exchange (NYSE) and the first day of admission to trading. The company said it is looking to partner with biopharmaceutical innovators who want to commercialise their products, leveraging Organon’s scale and presence in fast-growing international markets.